SLC1A5 and breast carcinoma: Additionally, we suggest that SLC1A5 is a potential therapeutic target for overcoming endocrine resistance and demonstrates the prognostic value of both SLC1A5 and TALDO1 as biomarkers for predicting endocrine therapy guide in luminal breast cancer.